Deputy director of administration, at First hospital of Quanzhou affiliated to Fujian Medical University, China.
Dr. Yu Xueping is an accomplished physician-scientist and leader in the field of infectious diseases. She holds a Ph.D. in Infectious Diseases from Fudan University Shanghai Medical College and currently serves as the Associate Chief Physician at Quanzhou First Hospital affiliated with Fujian Medical University. She is also Director of the Fujian Provincial Center for Bacterial and Fungal Infections and Deputy Director of the Key Laboratory for Screening and Prevention of Infectious Diseases in Fujian. A dedicated academic, Dr. Yu has guided numerous graduate students and is actively involved in international research networks. Her honors include nominations and awards at both provincial and national levels, recognizing her contributions to science and medicine. With over 78 published works, many in high-impact journals, Dr. Yu is a prominent voice in hepatology, infectious disease research, and clinical innovations. She is also a reviewer and editorial board member for top journals, reflecting her leadership in the global medical community.
Professional Profile
Scopus
ORCID
🎓 EducationÂ
Dr. Yu’s academic journey reflects her lifelong commitment to infectious disease research. She began her undergraduate studies in Clinical Medicine at Nanchang University Medical College (2004–2009), followed by a Master’s degree in Infectious Diseases from Fujian Medical University (2009–2012) under the mentorship of Prof. Zhijun Su. Her thirst for advanced research led her to pursue a Ph.D. in Infectious Diseases at the prestigious Fudan University Shanghai Medical College (2015–2018) under Prof. Jiming Zhang. During this time, she also participated in a joint research training program at the Shanghai Pasteur Institute, Chinese Academy of Sciences (2015–2016) with Dr. Bin Li. These experiences laid a strong foundation for her clinical and research expertise. Her training encompassed both fundamental and clinical perspectives, integrating molecular biology, immunology, and epidemiology to combat emerging infectious diseases—particularly liver-related conditions such as hepatitis B and C, cirrhosis, and liver failure.
đź©ş ExperienceÂ
Dr. Yu has cultivated over a decade of clinical and academic experience in infectious diseases. Starting in 2012 as a Resident Physician at Quanzhou First Hospital, she steadily rose to become Associate Chief Physician by 2021. She completed advanced clinical training at Huashan Hospital, affiliated with Fudan University, in 2020 and 2023. Her dual roles as clinician and mentor allow her to integrate research with bedside practice. Since 2021, she has also served as a Master’s supervisor, guiding the next generation of medical researchers. She leads major initiatives at the Fujian Provincial Center for Bacterial and Fungal Infections and is a key figure in multiple infectious disease collaborations at national and international levels. Her leadership has also been recognized through multiple hospital-level honors, including “Outstanding Doctor” and “Advanced Individual in the Fight Against COVID-19,” reflecting her vital role during the pandemic.
🔬 Research InterestsÂ
Dr. Yu Xueping’s research primarily focuses on the clinical and molecular aspects of difficult and emerging infectious diseases. Her interests span hepatitis B and C, liver cirrhosis (viral, alcoholic, immune, drug-induced), and acute-on-chronic liver failure (ACLF). She is particularly invested in the immunopathogenesis of liver diseases, T-cell exhaustion, and immune regulatory mechanisms in viral hepatitis. Her work has also covered bacterial and fungal infections affecting various organ systems, especially in immunocompromised patients. A significant part of her research involves translational medicine—integrating clinical findings with laboratory investigations to improve diagnosis, treatment, and disease prediction models. She has participated in or led several multi-center drug clinical trials, some of which ranked nationally in trial quality. Dr. Yu is also active in creating predictive models for liver disease and exploring the role of immune checkpoints like BTLA and G-MDSCs in liver failure progression. Her interdisciplinary work bridges clinical practice and cutting-edge research.
🏆 AwardsÂ
Dr. Yu has received numerous accolades for her contributions to science and medicine. At the provincial level, she is a recipient of the Fujian Youth Science and Technology Award (2023), a nominee for the China Youth Science and Technology Award (2024), and was selected for the “Ten Thousand Talents Plan” and “Chu Ying Plan” for top young talents. Her research has been recognized with the Fujian Provincial Science and Technology Progress Award (3rd Class, 2023) and two Fujian Medical Science and Technology Awards (2nd Class, 2020, 2022). Her clinical excellence was further acknowledged when she earned prizes in national-level case competitions and speaking forums, including First Prize at the 2018 Huaxia Liver Disease Forum, and Second Prize at the 2023 China Drug-Induced Liver Injury Forum. These awards underscore her impactful contributions to infectious disease diagnostics, therapeutics, and public health.
đź“šTop Noted PublicationsÂ
Dr. Yu has published 78 academic papers, with over 50 indexed by SCI journals. Of these, 35 were as first or corresponding author. Her work has appeared in prestigious journals such as Nature Communications, Journal of Hepatology, and Frontiers in Medicine. Her most cited works focus on the immune regulatory pathways in hepatitis B and the predictive models for liver pathology. Selected recent publications include:
🔬 1. Accuracy of International Guidelines in Identifying Normal Liver Histology
Journal: Journal of Viral Hepatitis (2025)
Lead Author: Yidi Jia
-
Focus: Evaluates how well international guidelines predict normal liver histology in Chinese HBeAg-positive chronic HBV patients.
-
Relevance: Important for diagnostic accuracy and optimizing treatment decisions in specific populations.
đź’‰ 2. Effect of HBeAg/anti-HBe Coexistence on Seroconversion
Journal: Therapeutic Advances in Gastroenterology (2025)
Lead Author: Kaimin Song
-
Focus: Studies the coexistence of HBeAg and anti-HBe in treatment-naïve patients receiving peginterferon-α.
-
Finding (likely): This serological profile might influence response rates or delay seroconversion.
🩺 3. Dyslipidemia’s Impact on HBsAg Clearance
Journal: BMC Infectious Diseases (2024)
Lead Author: Kaimin Song
-
Focus: Examines whether dyslipidemia affects HBsAg clearance in patients previously treated with nucleos(t)ide analogues and then given peginterferon alfa.
-
Clinical implication: Lipid metabolism may play a role in immune-mediated viral clearance.
⚠️ 4. BTLA and CD4+ T-cell Exhaustion in ACLF
Journal: Nature Communications (2024)
Lead Author: Xueping Yu
-
Focus: Demonstrates that BTLA contributes to infection and mortality in acute-on-chronic liver failure (ACLF) via CD4+ T-cell exhaustion.
-
Significance: Highlights immune exhaustion pathways as therapeutic targets in advanced liver disease.
📨 5. Immunomodulatory Effects of TDF and ETV
Type: Letter
Authors: Xueping Yu et al.
-
Focus: Briefly discusses the immunomodulatory properties of tenofovir disoproxil fumarate (TDF) and entecavir (ETV) beyond viral suppression.
-
Relevance: Shows interest in the immune effects of antiviral agents—not just their viral kinetics.
Conclusion
Dr. Yu Xueping is highly deserving and exceptionally well-qualified for the Best Researcher Award. His sustained contributions to infectious diseases, impactful publication record, strong leadership in research and clinical trials, and recognition at provincial and national levels mark him as a leading figure in his field.